Board Member & Strategic Advisor
Tom Lytle is an experienced pharmaceutical and biotechnology executive with over 35 years of industry experience. During his career, he has held positions of increasing responsibility in pharmaceutical and biotechnology sales, marketing, marketing management, new product commercialization, and executive management with market leading companies, including Pfizer, Lederle, Cytogen and Amgen. He has worked in multiple therapeutic categories and has focused on building brands and developing talent to create high performing teams. He served on the Board of Directors and was Chief Operating Officer and Administrative Officer for Neogenix Oncology, a clinical stage oncology company.
He is President and Founder of Strategic Choices, LLC, a well-networked healthcare consulting firm focused on helping early stage companies set strategy, create options, and make decisions that shape their future. In late 2011, he became President & Chief Executive Officer for Melanovus Oncology, Inc, a late-pre-clinical stage company focused on melanoma and other skin cancers. In December 2014, he led Melanovus to a successful exit with the sale of the firm to Cipher Pharmaceuticals. As CEO, he led efforts to raise capital, secure a SBIR grant, expand the patent portfolio and advance the science. He has been an Adjunct Professor at the University of the Sciences in Philadelphia for over 6 years. In 1993, he retired from the US Army as a Colonel after 26 years of active and reserve service